Prostate cancer: The androgen receptor remains front and centre.

Philip J Saylor

Journal: Nature reviews. Clinical oncology 2013;10(3):126-8

PMID: 23381000

Full Text on Nature Publishing Group View on PubMed

Abstract

Address: Division of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7E, Boston, MA 02114, USA. [email protected].

DOI: 10.1038/nrclinonc.2013.14

Link outs

Free resources

Medical:

https://medlineplus.gov/prostatecancer.html

Other Literature Sources:

https://scite.ai/reports/23381000

Subscription / membership required

Full Text Sources:

MeSH Terms: Abiraterone Acetate, Adenocarcinoma, Androgen Antagonists, Androgens, Androstadienes, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase III as Topic, Disease-Free Survival, Docetaxel, Enzyme Inhibitors, Humans, Male, Molecular Targeted Therapy, Multicenter Studies as Topic, Neoplasm Proteins, Neoplasms, Hormone-Dependent, Prednisone, Prostatic Neoplasms, Randomized Controlled Trials as Topic, Receptors, Androgen, Steroid 17-alpha-Hydroxylase, Survival Rate, Taxoids

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.